They almost seem predisposed to say no. This particular drug, Adalurin for Duchenne muscular dystrophy. This is something I fought for during the battle for right to try when they are also The FDA advisory panel, after hearing from 50 or 60 Duchenne muscular families begging for this access to [Adalurin], voted 10 to 1 and said no. Fortunately, the FDA still allowed this drug be provided on a compassionate use basis. But now that's all coming to an end for some reason. (00:38–01:00)
CLAIM
Asserts that the FDA advisory panel voted 10 to 1 against approving Adalurin after hearing from families.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
